A Randomized, Double-blind, Parallel Group, Placebo Controlled, 6-week Study of the Effect of GW685698X Aqueous Nasal Spray 100mcg QD on the Hypothalamic Pituitary Adrenocortical (HPA) Axis in Children 2 to 11 Years of Age With Perennial Allergic Rhinitis (PAR).

GlaxoSmithKline1 site in 1 country90 target enrollmentFebruary 2005

ConditionsRhinitis, Allergic, Perennial

InterventionsGW685698X aqueous nasal spray

Overview

Phase: Phase 3
Intervention: GW685698X aqueous nasal spray
Conditions: Rhinitis, Allergic, Perennial
Sponsor: GlaxoSmithKline
Enrollment: 90
Locations: 1
Primary Endpoint: HPA axis function at baseline and after 6 weeks of treatment as measured by 24 hour urine and serial serum cortisol assessments in domiciled subjects
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age with perennial allergic rhinitis.

Registry

clinicaltrials.gov

Start Date

February 2005

End Date

July 2005

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel